News
Lend Lease sells King of Prussia mall
Lend Lease announced it has entered into an agreement to sell its interest in the King of Prussia shopping mall to the Morgan Stanley Prime Property Fund at a gross valuation of US$1.25 billion. Lend Lease has a 50%...
News
CHMP Issues Positive Opinion for Merck’s VICTRELIS
Merck, known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion under accelerated assessment1 recommending approval of the...
News
RAUMEDIC and Sartorius Stedim Biotech Sign Partnership Agreement
Sartorius Stedim Biotech (SSB), an international leading pharma and biotech supplier, and RAUMEDIC, a leading worldwide OEM manufacturer of medical- and pharmaceutical-grade polymer components and systems, announced the signing of a global partnership agreement. ...
News
Takeda to Acquire Nycomed
Takeda Pharmaceutical Company Limited jointly announced that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis. The boards of directors of...
News
Clinical phase III studies of Lu AA21004 presented for the first time at the 2011 Annual Meeting
H. Lundbeck A/S announced the presentation of new data from the clinical phase III program of Lu AA21004, an investigational compound for the treatment of adult patients with major depressive disorder (MDD), at the 2011 Annual Meeting of the...
News
Mylan Launches Generic Version of Percodan Tablets
Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone and Aspirin Tablets USP, 4.8355 mg/325 mg, based on an agreement with licensing partner Coastal Pharmaceuticals. This product is the generic version of Endo Pharmaceuticals' Percodan® Tablets,...
News
Sun Pharma announces USFDA approval for DOCEFREZTM for Injection
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its New Drug Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial. This NDA provides for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.